Frizziero, M;
Kilgour, E;
Simpson, KL;
Rothwell, DG;
Moore, DA;
Frese, KK;
Galvin, M;
... Dive, C; + view all
(2022)
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
Clinical Cancer Research
, 28
(10)
pp. 1999-2019.
10.1158/1078-0432.CCR-21-3058.
Preview |
Text
EMS140832.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers garnering interest as they become more commonly encountered in the clinic. This is due to improved diagnostic methods and the increasingly observed phenomenon of “NE lineage plasticity,” whereby nonneuroendocrine (non-NE) epithelial cancers transition to aggressive NE phenotypes after targeted treatment. Effective treatment options for patients with PD-NEC are challenging for several reasons. This includes a lack of targetable, recurrent molecular drivers, a paucity of patient-relevant preclinical models to study biology and test novel therapeutics, and the absence of validated biomarkers to guide clinical management. Although advances have been made pertaining to molecular subtyping of small cell lung cancer (SCLC), a PD-NEC of lung origin, extrapulmonary (EP)-PD-NECs remain understudied. This review will address emerging SCLC-like, same-organ non-NE cancer-like and tumor-type–agnostic biological vulnerabilities of EP-PD-NECs, with the potential for therapeutic exploitation. The hypotheses surrounding the origin of these cancers and how “NE lineage plasticity” can be leveraged for therapeutic purposes are discussed. SCLC is herein proposed as a paradigm for supporting progress toward precision medicine in EP-PD-NECs. The aim of this review is to provide a thorough portrait of the current knowledge of EP-PD-NEC biology, with a view to informing new avenues for research and future therapeutic opportunities in these cancers of unmet need.
| Type: | Article |
|---|---|
| Title: | Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1158/1078-0432.CCR-21-3058 |
| Publisher version: | http://dx.doi.org/10.1158/1078-0432.ccr-21-3058 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Biomarkers, Tumor, Carcinoma, Neuroendocrine, Humans, Infant, Newborn, Lung, Lung Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10188146 |
Archive Staff Only
 |
View Item |
